“Poor nutrition and poor body weight, as well as a loss of muscle mass, can increase the risk of developing GVHD,” says Michelle Bratton, RD, former nutrition educator with the LLS’s ...

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 per ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues. Ocular manifestation of ...

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease ...

2月17日，是移植物抗宿主病日（GVHD ...

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025;1-11.

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...